Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

被引：54

作者：

Janjigian, Y. Y. ^{[1
]}

Al-Batran, S-E. ^{[2
]}

Wainberg, Z. A. ^{[3
]}

Van Cutsem, E. ^{[4
,5
]}

Molena, D. ^{[6
]}

Muro, K. ^{[7
]}

Hyung, W. J. ^{[8
]}

Wyrwicz, L. S. ^{[9
]}

Oh, D. Y. ^{[10
,11
]}

Omori, T. ^{[12
]}

Moehler, M. ^{[13
]}

Garrido, M. ^{[14
,15
]}

Oliveira, S. Cunha Sousa ^{[16
]}

Liberman, M. ^{[17
]}

Oliden, V. Castro ^{[18
]}

Bilici, M. ^{[19
]}

Kurland, J. F. ^{[20
]}

Xynos, I. ^{[21
]}

Mann, H. ^{[21
]}

Tabernero, J. ^{[22
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY USA

[2] Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany

[3] UCLA, David Geffen Sch Med, Dept Gastrointestinal Med Oncol, Los Angeles, CA USA

[4] Univ Hosp Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium

[5] Katholieke Univ Leuven, Leuven, Belgium

[6] Mem Sloan Kettering Canc Ctr, Div Thorac Surg, New York, NY USA

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[8] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[10] Seoul Natl Univ Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea

[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[12] Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan

[13] Johannes Gutenberg Univ Clin, Res Ctr Immunotherapy FZI, Mainz, Germany

[14] SAGA Clin Trial Ctr, Hemato Oncol Dept, Santiago, Chile

[15] Univ Mayor, Santiago, Chile

[16] Clin Res Ctr, Northern Riograndense League Canc, Clin Oncol, Natal, RN, Brazil

[17] Ctr Hosp Univ Montreal Ctr Rech CHUM, Dept Surg, Div Thorac Surg, Montreal, PQ, Canada

[18] Natl Inst Neoplast Dis INEN, Med Oncol Dept, Lima, Peru

[19] Ataturk Univ, Dept Med Oncol, Fac Med, Erzurum, Turkiye

[20] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA

[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England

[22] UVic UCC, Vall Hebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, IOB Quiron, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.074

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA73

引用

页码：S1315 / S1316

页数：2